Massimo Aglietta
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Hematology top 0.2%
- Hematopoietic Stem Cell Transplantation
Papers in
- Oncology 183
- HER2/EGFR in Cancer Research 45
- CAR-T cell therapy research 33
- Cancer Treatment and Pharmacology 21
- Hematology 94
- Hematopoietic Stem Cell Transplantation 43
- Acute Myeloid Leukemia Research 23
- Co-authors
- Filippo Montemurro (59 shared papers)Fiorella Sanavio (54 shared papers)Giorgio Valabrega (47 shared papers)Wanda Piacibello (77 shared papers)Federico Bussolino (25 shared papers)Franca Fagioli (28 shared papers)Loretta Gammaitoni (51 shared papers)Dario Sangiolo (50 shared papers)
- Journals
- Blood (25 papers)Annals of Oncology (24 papers)Cancers (13 papers)BMC Cancer (11 papers)Clinical Cancer Research (9 papers)
- Partner nations
- ItalyUnited StatesBelarus
In The Last Decade
Massimo Aglietta
406 papers receiving 19.4k citations
Massimo Aglietta's Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 8.3k
- Hematology 2.7k
- Immunology 3.1k
- Pulmonary and Respiratory Medicine 4.1k
- Cancer Research 1.8k
Countries citing papers authored by Massimo Aglietta
This map shows the geographic impact of Massimo Aglietta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Aglietta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Aglietta more than expected).
Fields of papers citing papers by Massimo Aglietta
This network shows the impact of papers produced by Massimo Aglietta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Aglietta. The network helps show where Massimo Aglietta may publish in the future.
Co-authors
The 25 scholars most cited alongside Massimo Aglietta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 416 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Hit paper breakdown → | 2012 | 1703 |
| 2 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Hit paper breakdown → | 2018 | 1672 |
| 3 | Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate Hit paper breakdown → | 1989 | 574 |
| 4 | 2007 | 519 | |
| 5 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 496 |
| 6 | 1983 | 400 | |
| 7 | 2007 | 394 | |
| 8 | 1997 | 388 | |
| 9 | 2011 | 306 | |
| 10 | 2014 | 288 | |
| 11 | 1999 | 275 | |
| 12 | 2005 | 272 | |
| 13 | Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. | 1981 | 214 |
| 14 | 1986 | 207 | |
| 15 | 2006 | 204 | |
| 16 | 2012 | 202 | |
| 17 | 2004 | 199 | |
| 18 | 2014 | 186 | |
| 19 | 2019 | 185 | |
| 20 | Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study Hit paper breakdown → | 2023 | 178 |
About Massimo Aglietta
Massimo Aglietta is a scholar working on Oncology, Hematology, Immunology, Genetics and Pulmonary and Respiratory Medicine, having authored 416 papers that have together received 20.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (45 papers), Hematopoietic Stem Cell Transplantation (43 papers), CAR-T cell therapy research (33 papers), Immune Cell Function and Interaction (31 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (31 papers), Acute Myeloid Leukemia Research (23 papers), Cancer Treatment and Pharmacology (21 papers) and Immunotherapy and Immune Responses (21 papers). The work is most often cited by research in Oncology (8.3k citations), Hematology (2.7k citations), Immunology (3.1k citations), Pulmonary and Respiratory Medicine (4.1k citations) and Cancer Research (1.8k citations). Massimo Aglietta has collaborated with scholars based in Italy, United States and Belarus. Frequent co-authors include Filippo Montemurro, Fiorella Sanavio, Giorgio Valabrega, Wanda Piacibello, Federico Bussolino, Franca Fagioli, Loretta Gammaitoni, Dario Sangiolo, Giuliana Cavalloni and Giovanni Camussi. Their work appears in journals such as Blood, Annals of Oncology, Cancers, BMC Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.